Journal of Oncology Pharmacy Practice最新文献

{"title":"Cisplatin nephrotoxicity in cervical and ovarian cancer: Incidence, risk factors, and prevention in a resource-limited setting.","authors":"Fasil Tefera Tassew, Abdisa Tufa Bedada","doi":"10.1177/10781552261494170","DOIUrl":"https://doi.org/10.1177/10781552261494170","url":null,"abstract":"<p><p>BackgroundCisplatin induced nephrotoxicity affects approximately 30% of treated patients and remains the primary dose limiting toxicity of this essential chemotherapeutic agent. In resource-limited settings, inconsistent implementation of prevention protocols may increase nephrotoxicity risk, yet prospective data from African populations remain scarce.MethodsWe conducted a prospective cohort study of 76 women with cervical or ovarian cancer receiving cisplatin based chemotherapy at Tikur Anbessa Specialized Hospital (TASH), Ethiopia. Comprehensive risk factor assessment included demographic, clinical, and treatment related variables. All patients received standardized prevention protocols including intravenous hydration (2.5-3.5 L normal saline per cycle), antiemetic prophylaxis, and serial renal function monitoring. The primary outcome was the incidence of cisplatin induced nephrotoxicity graded by creatinine elevation according to CTCAE v5.0 criteria. Secondary outcomes included risk factor associations and prevention strategy effectiveness.ResultsThe cohort comprised 45 cervical (59.2%) and 31 ovarian (40.8%) cancer patients with mean age 52.4 ± 11.8 years. All 76 enrolled patients completed the primary treatment monitoring period. Despite universal hydration, nephrotoxicity of any grade occurred in 76.3% (58/76), predominantly Grade 1 (56.6%, 43/76). Severe nephrotoxicity (Grade ≥3) occurred in only 5.3% (4/76), with no Grade 4 events. Independent risk factors for moderate to severe nephrotoxicity included baseline eGFR <75 mL/min/1.73m² (OR 4.72, 95% CI 1.89-11.78, p = 0.001), advanced age ≥60 years (OR 3.41, 95% CI 1.28-9.07, p = 0.014), and cumulative cisplatin dose >200 mg/m² (OR 2.93, 95% CI 1.14-7.52, p = 0.025). Magnesium supplementation was associated with reduced nephrotoxicity severity (p = 0.042). The mannitol forced diuresis subgroup showed lower 48-h creatinine elevation compared to hydration alone (0.18 ± 0.11 vs 0.31 ± 0.18 mg/dL, p = 0.038).ConclusionsIn this Ethiopian cohort, cisplatin induced nephrotoxicity was common when assessed by serial creatinine monitoring, but implementation of structured prevention protocols effectively limited progression to clinically significant renal impairment. Baseline renal function, age, and cumulative dose independently predicted nephrotoxicity risk. These findings support the feasibility of safe cisplatin administration in resource-limited settings through protocolized prevention strategies.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261494170"},"PeriodicalIF":1.3,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149137097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence, onset, severity, risk factors, and rechallenge strategies of etoposide infusion-related reactions in adults: A retrospective cohort study.","authors":"Maci T Wong, Rachel M MacMillan, Glenn S Myers, Liam S Berrigan, Jayden Bc Jones, Taylor F White, Andrew J Flewelling","doi":"10.1177/10781552261494198","DOIUrl":"https://doi.org/10.1177/10781552261494198","url":null,"abstract":"<p><p>IntroductionThe estimated incidence of etoposide infusion-related reactions (IRRs) in the general population is 1-3%, with pediatric reports ranging from 1-27.1%, and adult data being limited. Inconsistent documentation of IRR onset and underreporting of mild reactions have contributed to gaps in the literature. Rechallenging practices following infusion interruption are not standardized. This study aimed to evaluate the incidence, onset, severity, risk factors, and rechallenge strategies for etoposide IRRs in adults.MethodsThis retrospective cohort study included adult patients who initiated intravenous etoposide at Horizon Health Network in New Brunswick, Canada, between January 1, 2023, and June 30, 2025. Descriptive statistics were used to characterize IRR incidence, onset, severity, and rechallenge strategies. Demographic and treatment characteristics were compared between patients with and without IRRs using chi-square, Fisher's exact, and Mann-Whitney U tests.ResultsAmong 199 identified patients, 29 experienced at least one etoposide IRR (14.6%), most commonly occurring during cycle 2 (51.7%), with grade 2 reactions (65.5%) predominating. No demographic or treatment-related factors were significantly associated with IRR occurrence. Rechallenge strategies primarily involved infusion rate reduction and addition of diphenhydramine, corticosteroids, and famotidine following first IRRs. Switching to etoposide phosphate was more generally reserved for second IRRs.ConclusionThe incidence of etoposide IRRs in adults was higher than previously reported. Reactions may occur beyond initial infusions and can recur. Although no clear risk factors were identified, rechallenge strategies were generally successful and allowed for continuation of therapy following infusion interruptions.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261494198"},"PeriodicalIF":1.3,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149127777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fixed-dose glucarpidase use for high-dose methotrexate toxicity: A case series in Acute Lymphoblastic Leukemia.","authors":"Michael Whordley, Christopher Morris, Centaine L Snoswell, Fiona Swain, Gail Rowan, Marissa Ryan","doi":"10.1177/10781552261492219","DOIUrl":"https://doi.org/10.1177/10781552261492219","url":null,"abstract":"<p><p>IntroductionGlucarpidase 50 units per kilogram (units/kg) intravenously is indicated for high-dose methotrexate (HDMTX) toxicity, however lower doses are often used.Case seriesThree patients with Acute Lymphoblastic Leukemia were administered HDMTX 5g/m² intravenously over 24 h, developed toxicity, and required glucarpidase. Retrospective data collection included methotrexate (MTX) and creatinine levels and toxicity management. An acute kidney injury developed for all patients with serum creatinine increasing from 79 micromol/L to 172 micromol/L for patient A, 76 micromol/L to 130 micromol/L for patient B, and 67 micromol/L to 117 micromol/L for patient C. Forty-two hour MTX levels returned as 11, 13, 8.6 micromol/L (target is <1 micromol/L) and serum creatinine peaked at 250, 164, and 125 micromol/L for patients A, B, and C, respectively.Management and outcomeCalcium folinate, fluids, sodium bicarbonate, and diuretics were administered as indicated. All patients received glucarpidase 2000 units within 56 h of HDMTX commencing. MTX levels took an average of 12 days to fall to <0.1 micromol/L. Regain of normal renal function post-glucarpidase took 25 and 8 days for patients A and C respectively; patient B was lost to follow up.DiscussionWith evidence of efficacious glucarpidase dosing lower than 50 units/kg, including in this case series (2000 units), combined with its pharmacokinetic properties, 1000 units should be considered for adult patients less than 200 kilograms with a supratherapeutic MTX level of 200 micromol/L or less, from 24 h or 36 h (depending on the protocol used) to 60 h post-HDMTX commencement. This necessitates one 1000 units vial, reducing cost and potentially improving access.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261492219"},"PeriodicalIF":1.3,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149127762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of improvement in the STAT medication ordering process in a cancer hospital: A pre-post study.","authors":"Fatima Mela, Adeel Siddiqui, Omar Akhlaq Bhutta, Saba Mazhar, Muhammad Rehan Khan, Umar Javed","doi":"10.1177/10781552261495000","DOIUrl":"https://doi.org/10.1177/10781552261495000","url":null,"abstract":"<p><p>ObjectiveTo evaluate the effect of a computerized physician order entry (CPOE)-based intervention (a new 'ONCE' ordering frequency combined with a system-generated confirmation pop-up) on STAT order burden and on delayed STAT orders in a tertiary cancer hospital.MethodsA Pre-Post study design conducted at Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH&RC) in Lahore, Pakistan, utilizing the Hospital Information System (HIS) for the analysis of STAT medication orders, as a quality improvement project. A pop-up prompt, generated by the system, was incorporated into the STAT medication ordering process. The primary goal of this integration was to decrease the number of STAT orders and the associated delays.ResultsThe intervention was associated with a 51.5% decrease in STAT order volume (33,334 to 16,162 orders), with the overall STAT burden falling from 25.4% to 12.2% of all medication orders (p < 0.001). Delayed STAT orders declined by 55.4% (15,033 to 6711), from 11.5% to 5.1% of all orders. The two areas with the highest baseline burden showed marked declines: the Preoperative Holding Bay from 52.1% to 29.6% and the Intensive Care Unit from 43.6% to 24.5%. By the final study month, STAT orders comprised 7.8% of all orders, with delayed STAT orders comprising 3.3%.ConclusionThe implementation of a new frequency of ONCE and system-generated pop-ups has proven to be an effective method for reducing both the volume and delays of STAT orders.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552261495000"},"PeriodicalIF":1.3,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149127760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of dose rounding and drug vial optimization for reducing anticancer drug waste.","authors":"Tomohiko Harada, Eiseki Usami, Takuya Aso, Natsumi Yokoyama, Yukari Imanishi, Isao Suzuki, Akihiro Moriya, Hiroki Asano, Makiko Go, Michio Kimura, Yoshihiro Noguchi, Tomoaki Yoshimura","doi":"10.1177/10781552251341567","DOIUrl":"10.1177/10781552251341567","url":null,"abstract":"<p><p><b>Introduction:</b> Numerous injectable anticancer drugs are administered at varying doses based on the body surface area and weight of the patients, often resulting in a certain volume of residual medication. Several anticancer drugs are expensive, thus, their increased use has led to a corresponding increase in drug waste and healthcare costs. Two potential solutions to this issue include drug vial optimization (DVO) and dose rounding (DR). However, DR has rarely been implemented in Japan. Here, we evaluated DVO and DR to assess whether DR could be a viable strategy to reduce the number of anticancer drugs discarded and minimize drug-related costs in Japan. <b>Methods:</b> Patients who received bevacizumab, ramucirumab, gemcitabine, or levofolinate between January and December 2023 at Kanagawa Prefectural Ashigarakami Hospital (Ashigarakami) and Ogaki Municipal Hospital (Ogaki) were included in this study. Actual quantities used for each anticancer drug were extracted from electronic medical records, and the quantities used of drugs during the application of DVO and DR were calculated. Based on these findings, we estimated the reduction in drug waste and the associated cost savings for DVO and DR. <b>Results:</b> DR was more effective than DVO in minimizing the waste of drugs, with 0% waste for gemcitabine at Ogaki and 0% waste for levofolinate at both institutions. <b>Conclusion:</b> Compared with DVO, DR is not influenced by the number of patients treated or the volume of anticancer drugs administered, making it feasible for implementation across a wide range of institutions and a highly effective strategy for minimizing waste. DR should be advocated as a key approach for reducing drug costs in Japan in the future.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1352-1360"},"PeriodicalIF":1.3,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long term and simulated in-use stabilities of irinotecan chemotherapy polyolefin infusion bags in dose banding conditions.","authors":"Claire Andre, Lydie Lethier, Yves Claude Guillaume","doi":"10.1177/10781552251338763","DOIUrl":"10.1177/10781552251338763","url":null,"abstract":"<p><p>PurposeThe dose-banding of irinotecan provides the opportunity to anticipate the preparation of this anticancer drug on condition of carrying out stability studies. The aim of this study was to develop and validate a HPLC method for measuring the concentration of irinotecan and to evaluate its long-term stability at standardized rounded doses in polyolefin (POF) infusion bags at 4°C and protected from daylight. Microbiological and Physical stability tests were periodically performed including visual inspection, turbidity, lightness and chromaticity measurements. In addition, in a simulated in-use study, irinotecan quantification was also performed on the solution emitted from the POF infusion bags on a short period (24 h), at room temperature (25°C) and in daylight.MethodsThe HPLC with photodiode array (PDA) detector method was developed and validated (linearity, precision, accuracy, limits of detection and quantification, robustness and degradation test). Diluted irinotecan infusion solutions were aseptically prepared by further dilution of irinotecan stock solution with 0.9% sodium chloride in POF bags at banded doses 200 mg, 300 mg and 370 mg, the three most frequently produced doses in the pharmacy department. The POF bags were stored under refrigeration (4°C) in the dark (long term stability conditions) or at room temperature (25°C) in daylight for a short period 24 h (simulated in-use conditions). Microbiological tests were carried out and the physical and chemical stabilities were evaluated respectively through visual inspection, turbidity, lightness, chromaticity measurements and through chromatographic assays, pH and osmolality monitoring.ResultsThe long - term stability of irinotecan at selected standardized rounded doses (200 mg-300 mg-370 mg) in NaCl 0.9% polyolefin bags was confirmed for at least 84 days at 4 °C and in the dark. Microbiological tests performed on the samples were negative. As well, during the simulated in-use study, no signs of chemical instability were observed.ConclusionsA simple, accurate and stability-indicating HPLC method was developed to determine irinotecan concentrations in dose-banding conditions. As well, this present work including HPLC peak width, lightness and chromaticity measurements of a cytotoxic drug during the time of storage may be a guidance in stability studies. This study supports a centralized production of irinotecan in accordance with the studied conditions.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1314-1323"},"PeriodicalIF":1.3,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144031233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retrospective cross-sectional study of drug utilisation and expenditure of anticancer drugs at zonal referral hospital central, Tanzania.","authors":"Kauke Bakari Zimbwe, Yusto Julius Yona, Alphonce Bilola Chandika, Humphrey Sawira Kiwelu, Mkapa Faustine Madebele, Charity Alphonce Chiwambo","doi":"10.1177/10781552251339126","DOIUrl":"10.1177/10781552251339126","url":null,"abstract":"<p><p>BackgroundEnsuring the widespread availability and accessibility of anticancer medications is crucial. This aligns with the World Health Organization's recommendation to achieve a coverage of over 80%.ObjectiveThis study aimed to analyse anticancer procurement data to identify utilisation patterns and expenditures, aiding future planning and investment in oncology pharmacy services. The findings can enhance resource allocation, ensuring better availability and accessibility for patient care.MethodologyThe retrospective cross-sectional descriptive study meticulously examined procurement, prescribing, and dispensing records at Benjamin Mkapa Hospital (BMH).ResultsThe expenses linked to anticancer medications have markedly escalated, experiencing successive increases of 5.74%, 16.12%, 24.10%, and 17.73% in 2020, 2021, 2022, and 2023, respectively. Notably, Bevacizumab, Rituximab, Trastuzumab, Docetaxel, Paclitaxel and Goserelin (3.6 mcg) were the most frequently utilised anticancer medications, accounting for over 64% of total drug dispensation from 2020 to 2023. Concurrently, the availability of essential anticancer treatments significantly improved, rising from 54% in 2020 to 84% in 2022 and 2023. Over the four-year period (2020-2023), anticancer drugs comprised a mere 2.8% (580 out of 20,542) of all prescriptions, predominantly for patients aged 46 and above, with 85% covered by health insurance. Breast, prostate, and stomach cancers stood out as the most prevalent, representing over 40%, 30%, and 5% of all reported cases, respectively.ConclusionThe oncology pharmacy department at BMH improved anticancer drug availability from 54% to 84% over four years, primarily treating breast, prostate, and stomach cancers with Taxane and ACT regimens.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1331-1343"},"PeriodicalIF":1.3,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144497367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The burden of drug interactions in oncology: Prevalence, risk factors and severity in a tertiary care hospital.","authors":"Shreya Kolte, Srinivasa Chelluri, Priti Dhande","doi":"10.1177/10781552251338769","DOIUrl":"10.1177/10781552251338769","url":null,"abstract":"<p><p>BackgroundPatients ongoing cytotoxic chemotherapy concomitantly receive drugs for prevention of adverse effects as well as treatment for comorbidity. Exposure to such large number of drugs increases the chances of drug-drug interactions. This study was planned to determine the potential drug interactions and risk factors associated with them, in cancer patients of a tertiary care teaching hospital.MethodologyProspective, observational study conducted in the adult and pediatric oncology units. Data of medications received by each patient entered in UpToDate software to get the information about potential drug interactions (pDDI). Any observed outcome due to the drug interaction was noted down along with its management. Welch's independent samples t-test was conducted to identify quantitative factors that had a significant impact on observed Drug-Drug Interactions (oDDI). Pearson's correlation coefficient was calculated for all quantitative variables.ResultsOut of 110 patients, pDDI were found in 93.6% of them and actually occurred in 49.1% of these patients. Most of the pDDI were between the co-administered drugs (67.1%) in whom supportive medications were given or patient monitored. Significant association was found between the number of drug-drug interactions (DDIs) and age of the patient (p = 0.020), total number of drugs used (p < 0.001), number of drugs for comorbidities (p = 0.024), and number of co-administered medications (p < 0.001).ConclusionHigh prevalence of drug interactions among cancer patients indicates the need to develop protocols for monitoring and effective communication between healthcare providers for safe and effective care.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1324-1330"},"PeriodicalIF":1.3,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143970197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial intelligence-based muscle analysis risk assessment of treatment-related toxicity in metastatic colorectal cancer.","authors":"Matthew Lei, Ryan D Nipp, Erica Tavares, Uvette Lou, Erica Grasso, Stephanie Mui, J Peter Marquardt, Till D Best, Emily E Van Seventer, Anurag Saraf, Ismail Tahir, Nora K Horick, Florian J Fintelmann, Eric J Roeland","doi":"10.1177/10781552251338048","DOIUrl":"10.1177/10781552251338048","url":null,"abstract":"<p><p>IntroductionUp to 60% of adults with metastatic colorectal cancer (mCRC) receiving combination cytotoxic chemotherapy may experience loss of skeletal muscle mass and function. This study explores associations of artificial intelligence (AI)-based skeletal muscle assessment with hematologic toxicity and chemotherapy relative dose intensity (RDI) in adults with mCRC receiving standard combination chemotherapy.MethodsWe conducted a retrospective analysis of adults with mCRC receiving first-line FOLFOX or FOLFIRI over 6 months (≤12 cycles) from 1/2011 to 11/2018. We used a validated AI-based skeletal muscle assessment on baseline (prior to starting chemotherapy) computed tomography scans to determine skeletal muscle index (SMI, cm²/m²), categorizing low SMI using independent sex-specific cut-off values. We sought to evaluate the association between low SMI and the incidence of grade ≥3 (G ≥ 3) cytopenia over 6 months. Secondary endpoints included time to G ≥ 3 cytopenia and RDI.ResultsOverall, 126 adults met inclusion (median age = 61 years [range, 29-85]; 56 [44%] female) with a median BMI of 26.6 kg/m² (IQR, 24.1-30.5 kg/m²), including 59 (47%) with a low SMI. G ≥ 3 neutropenia incidence was higher in adults with low SMI (31% vs. 15%, p = 0.036). There was no difference for other G ≥ 3 cytopenias (39% vs 24%, p = 0.067) or median time to G ≥ 3 neutropenia (p = 0.053). Patients with a low SMI had a lower 5FU-bolus RDI (p = 0.045).ConclusionAdults with mCRC receiving first-line chemotherapy with low SMI experienced more G ≥ 3 neutropenia and decreased 5-FU bolus RDI.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1306-1313"},"PeriodicalIF":1.3,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144000713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Age-related adverse effects of Tamoxifen in female breast cancer patients: Insights from the FDA's adverse event reporting system.","authors":"Yuting Chen, Weitao Lu, Li Xin, Xu Tang, Jing Wang, Huancun Feng","doi":"10.1177/10781552251338040","DOIUrl":"10.1177/10781552251338040","url":null,"abstract":"<p><p>Background<b>Tamoxifen is an effective treatment for hormone receptor-positive breast cancer (BC)</b>. Despite its effectiveness, there have been many reports of adverse reaction. <b>However, the relationship between Tamoxifen-related adverse events (ADEs) and patient age remains unclear</b>.Aim<b>To enhance clinical medication guidance and drug safety by identifying age-specific ADEs associated with Tamoxifen therapy in female breast cancer patients, thereby offering a more robust foundation for evidence-based clinical practice</b>.MethodsADEs reports of Tamoxifen from the FAERS database were extracted from the first quarter of 2004 to the second quarter of 2023. Reporting odds ratio (ROR) data analysis strategy was used for mining signal strength that represents age differences in ADEs related to Tamoxifen.ResultsThe number of <b>efficient ADE signals associated with Tamoxifen</b> for female BC included in the analysis was 338 in premenopausal women, 847 in perimenopause and 1525 in postmenopause respectively. Our study showed age differences in three age groups of ADEs with Tamoxifen in female BC. <b>Perimenopausal and postmenopausal women receiving tamoxifen therapy demonstrated a significantly higher incidence of adverse drug reactions, particularly involving the gastrointestinal tract, renal/urinary systems, hematologic/lymphatic systems, endocrine functions, and immune responses</b>. It was particularly concerned that ADEs associated with ear and labyrinth disorders had only been reported in perimenopause.ConclusionAge differences was detected in ADE signals related to Tamoxifen. There were significant differences in Tamoxifen related ADEs of premenopausal, perimenopausal and postmenopausal women with BC in different systems. To ensure the safety of medicines, we should be aware of the age-related differences in ADEs and take appropriate preventive measures to reduce incidence of serious ADEs.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1295-1305"},"PeriodicalIF":1.3,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144031354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}